According to Mr. Sarad, "This experiment is incredibly important. I think we now have a mixture of nanotechnology based gene therapy products that can result in what might be called significant 'organismal rejuvenation'. We have seen regeneration of human tissues in the laboratory. How far this technology can ultimately go is hard to say, but I am optimistic that this is the first step in what will be referred to historically as the moment the age-barrier was broken."
This research may also change the way that cancer is treated in the future. For example, Mr. Sarad's company licensed and improved a protein based anti-cancer therapeutic noted in studies by the University of Nebraska Medical Center to be non-toxic and to cause long-term remission in 80% of all cancer, including difficult to treat neuronal cancer. The Corporation was working on increasing the remission rate further by delivering other tumor suppressor proteins. One or more tumor suppressor genes is corrupted, silenced, or deleted in almost all cancer. This therapeutic drug is being studied today at the country's third largest hospital the Cleveland Clinic in the treatment of cancer and restenosis. The hospital is also studying some of the corporation's tissue regeneration technologies.
Mr. Sarad's career in biotechnology has not been without controversy. In 2008 he was sanctioned by the SEC for alleged securities violations made while taking his company public in 2006. The company, Telomolecular Corp., achieved public status but its shares were later deregistered.
"The mistake I made was being young, inexperienced, and excited about the prospects of our technologies," said Mr. Sarad. "I failed to disclose that our management was inexperienced engineering an IPO and this may have been mislea
Copyright©2009 Vocus, Inc.
All rights reserved